US Most-Favoured-Nation Pricing and European Launches: What It Means for Market Access in Greece

Since the White House’s May 2025 executive order on most-favoured-nation (MFN) pricing, US drug prices have become increasingly linked to prices paid in other high-income countries. The result is a new factor in European launch decisions: a low list price in one European market can now carry consequences in the largest market in the world. For companies planning launches in Greece, and for the Greek system that relies on international price comparisons, this changes the calculation.

How MFN reaches Europe

The MFN policy aims to align US prices with the lowest prices paid in comparable countries. Many companies have since reached confidential agreements with the US administration. Whatever the mechanism, the effect is the same: European list prices are no longer purely a European matter. A modelling study published in The Lancet, covering 195 patented medicines, found that for around three in four of them, the revenue a company could lose from lower US prices would exceed its total annual sales in the reference countries. The authors warned that this creates an incentive to delay launches in lower-priced countries.

What the evidence shows so far

  • News reports based on industry data have described a substantial fall in new EU launches in the months following the executive order, although the cause is debated.
  • An unpublished European Commission analysis, reported by Euronews in September 2026, concluded that it is currently very difficult to link specific delays or price pressure directly to US policy.
  • Industry associations report that companies are reconsidering whether and when to launch in some European markets.

Why Greece is exposed

Greece sets prices through external reference pricing and has historically had some of the lower medicine prices in the EU. That combination already shapes launch sequencing, because a Greek price can feed into other countries’ reference baskets. MFN adds a further layer: if Greek list prices also become a reference point for US pricing, companies may be more cautious about early Greek launches, or may prefer confidential agreements that keep list prices higher than net prices.

The EU response

The EU pharmaceutical reform introduces new tools to encourage availability, including an obligation for marketing authorisation holders to supply a member state on request, with consequences for regulatory protection if they do not. Researchers note that such measures alone are unlikely to offset the financial pull of the US market. Joint clinical assessment under the HTA Regulation may also influence how quickly evidence is available across member states.

Practical implications for launch planning

  • Model the international price-referencing effects of a Greek launch, including any US linkage, before setting a list price
  • Consider managed entry agreements and confidential rebates as tools to protect list prices
  • Plan for possible supply requests under the EU reform
  • Engage early with the Greek HTA committee and the pricing authorities to understand evidence expectations

How PQRA helps

PQRA supports pricing and reimbursement strategy in Greece, including external reference pricing analysis, HTA submissions, managed entry agreements and launch sequencing across EU markets.

Talk to PQRA about your launch strategy for Greece

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *